LifeMD 

LifeMD, Inc. is a telehealth company, which engages in offering portfolio of direct-to-patient products and services. It combines virtual medical treatment with prescription medications and over-the-counter products. The firm's network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the United States. The firm's brands include Shapiro, Rex, and Nava. The company was founded in 1987 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AGF Management reports stable performance and growth opportunities in Q1 2023

AGF Management delivered stable performance in Q1 2023 with positive net sales and a dividend increase.
While facing challenges in certain business segments, AGF's strong cash position and investment portfolio provide a solid foundation.
Opportunities lie in capital allocation strategies, growth initiatives, and enhancing performance in key business areas.
Overall, AGF's focus on shareholder returns and strategic investments positions the company for future growth and success.

LifeMD surpasses Q1 expectations, eyes growth amid challenges

LifeMD's Q1 2023 performance exceeded expectations, driven by strong revenue and EBITDA results.
The company's strategic initiatives, including debt financing and AI integration, position it for growth.
Challenges lie in maintaining growth momentum, managing costs, and optimizing EBITDA margins.
Opportunities in partnerships, telehealth, and patient value enhancement offer avenues for future growth.

LifeMD reports strong Q2 performance and raises revenue guidance

LifeMD's Q2 performance reflects operational strength, revenue growth, and strategic initiatives driving positive results and financial stability.
While facing challenges in adjusted EBITDA guidance due to investments, the company maintains a strong position with record revenues and subscriber growth.
Opportunities for growth and expansion exist through the weight management program, partnerships, and focus on existing health care businesses.

LifeMD reports record Q3 revenue and profitability, eyes growth opportunities

LifeMD's Q3 results reflect a successful quarter marked by strong revenue, profitability, and subscriber growth. The company's focus on strategic initiatives and positive outlook for 2024 indicate a promising future with plans to accelerate momentum and deliver impressive results.

LifeMD reports record 2023 performance, eyes growth in weight management

LifeMD's strong performance in 2023 sets the stage for continued growth and profitability. The company's strategic focus on diversification, market expansion, and cost management positions it well for future success. Challenges in subscriber numbers and commercial partnerships require attention, but overall, LifeMD is on a positive trajectory.

LifeMD excels in Q2 with telehealth growth, WorkSimpli rebounds

LifeMD demonstrated robust performance in Q2 2024, driven by the success of its core telehealth business and strategic initiatives.
While facing challenges, WorkSimpli is making progress towards regaining peak profitability by addressing competitive and executional issues.
Opportunities lie in expanding service offerings, enhancing collaborations, and leveraging upcoming launches to drive growth and profitability for LifeMD.
Strategic focus on innovation, efficiency, and market differentiation positions LifeMD well for sustained success and revenue growth in the future.

LifeMD reports robust Q3 results, eyes Medicare expansion for growth

LifeMD's Q3 performance reflects strong revenue growth, operational improvements, and strategic expansion initiatives.
The company's focus on telehealth, men's health, and work simplification businesses is driving positive results.
While facing challenges in scaling operations and market competition, LifeMD is well-positioned for continued growth.
Opportunities in Medicare expansion, program enhancements, and market partnerships offer avenues for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LifeMD, Inc. is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded by Justin Schreiber on May 24, 1994 and is headquartered in New York, NY.

LifeMD, Inc. (NASDAQ:LFMD ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Justin Schreiber – Chief Financial Officer Marc Benathen – Chierf Financial Officer Conference Call Participants David Larsen – BTIG Marc Wiesenberger – B. Riley Securities Operator Good afternoon.

LifeMD, Inc. (LFMD) Q3 2022 Earnings Call Transcript

LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 88.89% and 2.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. (LFMD) Reports Q3 Loss, Misses Revenue Estimates

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the third quarter ended September 30, 2022. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, November 10, 2022, at 4:30 p.m. Eastern Time to discuss the results.

LifeMD, Inc. Reports Third Quarter 2022 Results

Strategic partnership enables direct-to-consumer food allergy clinic to provide convenient access to crucial peanut allergy threshold information Strategic partnership enables direct-to-consumer food allergy clinic to provide convenient access to crucial peanut allergy threshold information

LifeMD and Cleared Offer New Hope to Allergy Patients Through Strategic Partnership With Allergenis

LifeMD, Inc. (NASDAQ:LFMD ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Justin Schreiber - Chairman & CEO Marc Benathen - CFO Conference Call Participants Marc Wiesenberger - B. Riley Securities David Larsen - BTIG Operator Good day.

LifeMD, Inc. (LFMD) CEO Justin Schreiber on Q2 2022 Results - Earnings Call Transcript

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the second quarter ended June 30, 2022. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, August 11, 2022, at 4:30 p.m. Eastern time to discuss the results.

LifeMD, Inc. Reports Second Quarter 2022 Results

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company, today announced that it will report its financial results for the second quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

LifeMD, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 11, 2022

LifeMD, Inc. (LFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LifeMD, Inc. (LFMD) Upgraded to Buy: Here's Why

LifeMD, Inc. (NASDAQ:LFMD ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Justin Schreiber - Chairman & Chief Executive Officer Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG Marc Wiesenberger - B. Riley Securities Operator Good afternoon.

LifeMD, Inc. (LFMD) CEO Justin Schreiber on Q1 2022 Results - Earnings Call Transcript

LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 3.85% and 6.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. (LFMD) Reports Q1 Loss, Misses Revenue Estimates

NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the first quarter ended March 31, 2022. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, May 13, 2022, at 8:00 a.m. Eastern time to discuss the results.

LifeMD, Inc. Reports First Quarter 2022 Results

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that that management will participate in the following upcoming conferences:

LifeMD to Participate in the Upcoming May Conferences

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that that management will participate in the 21st Annual Needham Virtual Healthcare Conference on April 11th-14th, 2022.

LifeMD to Participate in the 21st Annual Needham Virtual Healthcare Conference

NavaMD's clinically studied, OTC skincare platform is protected by a global intellectual property portfolio and $50+ Million of third-party capital invested in R&D, clinical research, and manufacturing. NavaMD's clinically studied, OTC skincare platform is protected by a global intellectual property portfolio and $50+ Million of third-party capital invested in R&D, clinical research, and manufacturing.

LifeMD Launches Proprietary Over-the-Counter Skincare Line for Women, Expanding Teledermatology Offerings

LifeMD, Inc. (LFMD) CEO Justin Schreiber on Q4 2021 Results - Earnings Call Transcript

LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 25.64% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LifeMD, Inc. (LFMD) Reports Q4 Loss, Misses Revenue Estimates

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the fourth quarter and year ended December 31, 2021. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, March 7, 2022, at 4:30 p.m. Eastern time to discuss the results.

LifeMD Reports Fourth Quarter and Full Year 2021 Results

Presentations to Highlight Primary Care Technology Platform, Recently Acquired Allergy, Asthma & Immunology Business, and Details on 2022 Revenue Mix and Growth Strategy Presentations to Highlight Primary Care Technology Platform, Recently Acquired Allergy, Asthma & Immunology Business, and Details on 2022 Revenue Mix and Growth Strategy

LifeMD to Host 2022 Virtual Analyst and Investor Day

NEW YORK, Jan. 27, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that management will participate in the SVB Leerink Global Healthcare Conference on February 16th-18th, 2022 and Citi's 2022 Virtual Healthcare Conference on February 23rd-24th, 2022.

LifeMD to Participate in the Upcoming February Investor Conferences

LifeMD's DTC telehealth business is a market leader and is poised to show substantial growth after the recent launch of virtual primary care services and expansion into asthma. In addition, LifeMD owns a high-growth SaaS business likely already close to profitability with nearly 140k subscribers.

LifeMD: High Growth Telehealth Company Nearing Profitability

Apollo Medical Hlds

AMN Healthcare Services

The Zacks Medical - Services industry is growing on digital healthcare adoption. AMN, AMEH and LFMD are set to gain the most.

3 Medical Services Stocks to Buy Despite Near-Term Industry Woes

Acquisition of Cleared Further Diversifies LifeMD's Telehealth Offerings to Encompass  Allergy, Asthma, and Immunology

LifeMD Expands Patient Offerings by Acquiring Leading Allergy Telehealth Platform

NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced that management will participate in the following three investor conferences and one Panel event in January 2022 and be available for one-on-one meetings with investors. Details for each conference are as follows:

LifeMD to Participate in Upcoming January Investor Conferences

CEO Schreiber to discuss changes made possible via proprietary virtual care platforms CEO Schreiber to discuss changes made possible via proprietary virtual care platforms

LifeMD to Participate in Panel Presentation at LifeSci Partners Corporate Access Event 2022

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) --   LifeMD, Inc.  (“the Company”) (NASDAQ: LFMD) today announced that management will present at the Stephens Annual Investment Conference on Monday, November 29, 2021 and will host one-on-one meetings.

News for LifeMD Stock (LFMD)